Balance 2,3% glukose + 1,75 mmol Ca/l Նորվեգիա - Նորվեգերեն - Statens legemiddelverk

balance 2,3% glukose + 1,75 mmol ca/l

fresenius medical care deutschland gmbh - glukosemonohydrat / magnesiumkloridheksahydrat / natriumklorid / natriumlaktat / kalsiumkloriddihydrat - peritonealdialysevæske - 2.3 %

Balance 2,3% glukose + 1,25 mmol Ca/l Նորվեգիա - Նորվեգերեն - Statens legemiddelverk

balance 2,3% glukose + 1,25 mmol ca/l

fresenius medical care deutschland gmbh - glukosemonohydrat / magnesiumkloridheksahydrat / natriumklorid / natriumlaktat / kalsiumkloriddihydrat - peritonealdialysevæske - 2.3 %

Balance 4,25% glukose + 1,75 mmol Ca/l Նորվեգիա - Նորվեգերեն - Statens legemiddelverk

balance 4,25% glukose + 1,75 mmol ca/l

fresenius medical care deutschland gmbh - glukosemonohydrat / magnesiumkloridheksahydrat / natriumklorid / natriumlaktat / kalsiumkloriddihydrat - peritonealdialysevæske - 4.25 %

Balance 4,25% glukose + 1,25 mmol Ca/l Նորվեգիա - Նորվեգերեն - Statens legemiddelverk

balance 4,25% glukose + 1,25 mmol ca/l

fresenius medical care deutschland gmbh - glukosemonohydrat / magnesiumkloridheksahydrat / natriumklorid / natriumlaktat / kalsiumkloriddihydrat - peritonealdialysevæske - 4.25 %

Balance 1,5% glukose + 1,75 mmol Ca/l Նորվեգիա - Նորվեգերեն - Statens legemiddelverk

balance 1,5% glukose + 1,75 mmol ca/l

fresenius medical care deutschland gmbh - natriumklorid / natriumlaktat / kalsiumkloriddihydrat / magnesiumkloridheksahydrat / glukosemonohydrat - peritonealdialysevæske - / 1.5 %

MIBG [123I] 74 MBq/ ml Նորվեգիա - Նորվեգերեն - Statens legemiddelverk

mibg [123i] 74 mbq/ ml

curium netherlands b.v. - jobenguansulfat (123i) - injeksjonsvæske, oppløsning - 74 mbq/ ml

Tezspire Եվրոպական Միություն - Նորվեգերեն - EMA (European Medicines Agency)

tezspire

astrazeneca ab - tezepelumab - astma - legemidler for obstruktive sykdommer i luftveiene, - tezspire is indicated as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.

Adempas Եվրոպական Միություն - Նորվեգերեն - EMA (European Medicines Agency)

adempas

bayer ag - riociguat - hypertensjon, pulmonal - antihypertensive midler for pulmonal arteriell hypertensjon - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. effekten har vært vist i en pah befolkningen, herunder aetiologies av idiopatisk eller heritable pah eller pah assosiert med bindevev sykdom. paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.

Adempas 0.5 mg Նորվեգիա - Նորվեգերեն - Statens legemiddelverk

adempas 0.5 mg

abacus medicine a/s - riociguat - tablett, filmdrasjert - 0.5 mg

Adempas 1 mg Նորվեգիա - Նորվեգերեն - Statens legemiddelverk

adempas 1 mg

abacus medicine a/s - riociguat - tablett, filmdrasjert - 1 mg